

EL Reumatólogo

EL REUMATÓLOGO Nº 11

ARTÍCULO: Novedades en el tratamiento de las vasculitis asociadas a anticuerpos anticitoplasma de neutrófilo.

Dr. Javier Narvaez García.

Servicio de Reumatología. Hospital Universitario de Bellvitge.

BIBLIOGRAFÍA

1- Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al; CLEAR Study Group. Randomized trial of C5A receptor inhibitor avacopan in ANCA-associated vasculitis. *J Am Soc Nephrol* 2017;28:2756-67.

2- Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A, et al; CLASSIC Investigators. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. *ACR Open Rheumatol* 2020;2:662-71.

3- Merkel PA, Jayne DR, Wang C, Hillson J, Bekker P. Evaluation of the safety and efficacy of avacopan, a C5a Receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide / azathioprine: protocol for a randomized, double-blind, active-controlled, phase 3 trial. *JMIR Res Protoc* 2020;9:e16664.

4- Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. *N Engl J Med* 2021;384:599-609.

5- <https://www.clinicaltrials.gov/ct2/show/NCT03712345> (consultado el 27 de agosto del 2021).

6- <https://clinicaltrials.gov/ct2/show/NCT03895801> (consultado el 27 de agosto del 2021).

7- Ribes D, Belliere J, Piedrafita A, Faguer S. Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab. *Rheumatology (Oxford)* 2019;58:2335-7.

8- Huizenga N, Zonozi R, Rosenthal J, Laliberte K, Niles JL, Cortazar FB. Treatment of aggressive antineutrophil cytoplasmic antibody-associated vasculitis with eculizumab. *Kidney Int Rep* 2019 4;5:542-5.

9- Ennis D, Lee JK, Pagnoux C. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. *Expert Opin Biol Ther* 2019;19:617-30.

10- Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. *J Allergy Clin Immunol* 2010;125:267-70.

11. Moosig F, Gross WL, Herrmann K, Bremer JPh, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. *Ann Intern Med* 2011;155:341-3.

12. Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. *Clin Exp Rheumatol* 2012;30(1 Suppl 70):S62-5.

13- Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. *J Allergy Clin Immunol* 2010;12:1336-43.

14- Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *N Engl J Med* 2017;376:1921-32.

15- https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761122s000lbl.pdf (consultado el 27 de agosto del 2021).

16- Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheumatol* 2021;73:1366-83.

17- Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. *Autoimmun Rev* 2021; 20:102737.

18.- <https://clinicaltrials.gov/ct2/show/NCT02807103> (consultado el 27 de agosto del 2021).

19.- <https://clinicaltrials.gov/ct2/show/NCT03164473> (consultado el 27 de agosto del 2021).

20- Manka LA, Guntur VP, Denson JL, Dunn RM, Dollin YT, Strand MJ, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. *Ann Allergy Asthma Immunol* 2021;126:696-701.

21- Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. *J Allergy Clin Immunol Pract* 2021;9:1186-93.

22- Graziani A, Quercia O, Girelli F, Martelli A, Mirici Cappa F, Stefanini GF. Omalizumab treatment in patient with severe asthma and Eosinophilic Granulomatosis with Polyangiitis. A case report. *Eur Ann Allergy Clin Immunol* 2014; 46: 226-8.

23- Cisneros C, Segrelles G, Herráez L, González A, Martínez A, Girón R. Churg-Strauss syndrome in a patient treated with omalizumab. *J Investig Allergol Clin Immunol* 2013; 23: 515-6.

24- Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. *J Asthma* 2016; 53: 201-6.

25- Jachiet M, Samson M, Cottin V, Kahn JE, Le Guenno G, Bonniaud P, et al. French Vasculitis study group. Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic granulomatosis with Polyangiitis (Churg-Strauss): data on seventeen patients. *Arthritis Rheumatol* 2016; 68: 2274-82.

26- Celebi Sozener Z, Gorgulu B, Mungan D, Sin BA, Misirligil Z, Aydin O, et al. Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases. *World Allergy Organ* 2018;11:39.

27- Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 2007;18:2180-8.

28- Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. *Kidney Int* 2013; 84: 397-402.

29- Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. *N Engl J Med* 2020; 382: 622-31.

30- Zhu Y, Rao J, Liu L, Ou J, Li W, Xue C. The therapeutic effect of plasma exchange on ANCA-associated vasculitis: A meta-analysis. *Clin Nephrol* 2021;95:312-22.

31- Yamada Y, Harada M, Hara Y, Iwabuchi R, Hashimoto K, Yamamoto S, et al. Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis. *Arthritis Res Ther* 2021;23:28.

32- Bellos I, Michelakis I, Nikolopoulos D. The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. *Clin Rheumatol* 2021;40:1447-56.

33- Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R et al; RITAZAREM co-investigators. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. *Ann Rheum Dis* 2020;79:1243-9.

34- Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al; LoVAS Collaborators. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial. *JAMA*. 2021;325:2178-87.

35- <https://clinicaltrials.gov/ct2/show/NCT02169219> (consultado el 27 de agosto d